首页> 外国专利> ALGORYTHM OF DETERMINING INDIVIDUAL DEGREE OF RECURRENCE RISK AMONG CURED PATIENTS WITH NEWLY DIAGNOSED INFILTRATIVE PULMONARY TUBERCULOSIS

ALGORYTHM OF DETERMINING INDIVIDUAL DEGREE OF RECURRENCE RISK AMONG CURED PATIENTS WITH NEWLY DIAGNOSED INFILTRATIVE PULMONARY TUBERCULOSIS

机译:测定新诊断为感染性肺结核的患者中复发风险的个体度算法

摘要

FIELD: medicine.;SUBSTANCE: invention relates to medicine, namely to phthisiology, and can be used in TB clinics for formation of groups of higher risk of disease recurrence among cured patients with newly diagnosed infiltrative pulmonary tuberculosis for the moment of main treatment course end. Presence of risk factors of tuberculosis process progressing in remote period of observation is determined: group A - interruption of main treatment course, widespread infiltration for the moment of treatment beginning - 3 segments and more, drug resistance, contact with patient with open form of tuberculosis before beginning of treatment; group B - men, cavities of decay with 2 cm and more diametre at the beginning of treatment, duration of course treatment not higher than 180 doses, violation of regulated period of preventive fluoroexamination before detection of disease, interruption of hospital treatment. Presence of prognostically significant qualitative factors of type of residual post-tuberculosis changes (RTC) in remote period of observation is determined: contact with patient with open form of tuberculosis (x1), social status (x3), use of drugs (x4), completeness of hospital stage (x5), cavity of decay (x6), completeness of course treatment (x9), residual post-tuberculosis changes at the moment of detection (x10), massiveness of bacteria release (x12), in case if quality factor is absent it is equaled to 0, if it is present - to 1. Presence of prognostically significant quantitative factors of type of residual post-tuberculosis changes in remote period of observation is determined: number of affected lung segments (x2), age - years (x7), duration of course treatment - doses (x8), duration of intensive phase - doses (x11). After that, prognosis of "minor" (Y1) and "major" (Y2) RTC in remote period of observation are determined by formulas Y1 and Y2. On the basis of Y1 and Y2 values comparison conclusion about prediction of "minor" and "major" RTC is made. In case if one risk factor of tuberculosis progressing in remote period from group A or two and more from group B are absent, and 'minor" RTC are present, low degree of recurrence risk, requiring observation in III group of specialised dispensary registration for 1 year, is determined, if one factor of group A or two and more factors of group B are present and presence of "major" RTC, high degree of recurrence risk, requiring observation in III group of specialised dispensary registration for 3 years, is determined, if one factor of group A or two and more factors of group B are present and presence of "minor" RTC, medium degree of recurrence risk, requiring observation in III group of specialised dispensary registration for 2 years, is determined, and if, if one risk factor from group A or two and more from group B are absent, and presence of "major" RTC, medium degree of recurrence risk, requiring observation in III group of specialised dispensary registration for 2 years, is determined.;EFFECT: method allows to reduce frequency of recurrences due to improvement of specialised dispensary observation in group III of specialised dispensary observation of cured patients with newly diagnosed infiltrative pulmonary tuberculosis as the most frequent form of the disease.;4 tbl, 2 ex
机译:药物发明领域本发明涉及药物,即药理学,可用于结核病诊所,以在主要治疗过程结束时在新诊断为浸润性肺结核的治愈患者中形成较高的疾病复发风险组。 。确定在遥远的观察期中结核病进程进展的危险因素的存在:A组-主要治疗过程中断,在治疗开始时广泛渗透-3段及以上,耐药性,与开放型结核病患者接触在开始治疗之前; B组-男性,在治疗开始时蛀牙的直径大于2厘米,直径更大,疗程不超过180剂,在发现疾病之前违反了预防性氟检查的规定期限,中断了医院治疗。确定在遥远的观察期内是否存在残留的结核后变化(RTC)类型的预后重要定性因素:与开放型结核病患者(x1),社会地位(x3),药物使用(x4),医院阶段(x5)的完整性,腐烂腔(x6),疗程的完整性(x9),检测时残留的结核病后变化(x10),细菌释放的数量(x12)(如果质量因素)如果不存在,则等于0,如果存在-等于1。确定在遥远的观察期内残留的结核后残留变化类型的预后意义重大定量因素的存在:受影响的肺段数目(x2),年龄-岁(x7),疗程持续时间-剂量(x8),强化期持续时间-剂量(x11)。此后,通过公式Y1和Y2确定远程观察期间“小”(Y1)和“大”(Y2)RTC的预后。根据Y1和Y2值,得出有关“较小”和“较大” RTC预测的比较结论。如果不存在从A组远期发展到一个结核病的危险因素,或者从B组不存在两个或更多个,并且存在“较小的” RTC,则复发风险低,需要在III级专科配药注册中进行观察确定是否存在A组的一个因素或B组的两个或多个因素并且存在“重大” RTC的高复发风险,需要在III级专业药房注册中观察3年,如果存在A组一个因素或B组两个或更多个因素并且存在“较小的” RTC,则确定需要在III级专业药房注册中观察2年的中度复发风险,并且如果不存在来自A组的一个危险因素或来自B组的两个或多个危险因素,并且存在“较大的” RTC,则需要在III级专门药房注册中观察到的中等程度的复发风险是确定的效果:该方法可减少因新诊治的浸润性肺结核是最常见的治愈型治愈患者的第三次专业诊治观察中的专业诊治观察的改善而导致的复发频率。4tbl,2 ex

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号